Selegiline slows the progression of the symptoms of Parkinson disease

Abstract

The results of this long-term study confirm earlier findings indicating that selegiline delays the progression of the signs and symptoms of Parkinson disease.

Algorithms for the treatment of motor problems in Parkinson's disease

“…The DATATOP study22 found that the use of selegiline delays the need for levodopa in early PD, but most investigators have interpreted this as a symptomatic effect caused by MAO‐B inhibition that delays dopaminergic elimination from dopaminergic synapses. However, two randomized double‐blind long‐term Scandinavian studies comparing selegiline to levodopa in early PD found that patients receiving placebo needed progressively higher doses of levodopa than patients receiving selegiline 23, 24. This progressive increase in difference between the groups is difficult to explain only by symptomatic mechanisms, and a disease‐modifying effect was proposed in both studies, but has not been widely accepted internationally.…”

Mitochondrial proteomics as a selective tool for unraveling Parkinson’s disease pathogenesis

“…For instance, in rats, exposure to amphetamine and METH may cause destruction of striatal dopaminergic nerve fibers [135] and of depleted striatal DA content in human METH users [136]. However, large-scale trials of selegiline-use by PD patients failed to confirm these adverse effects [137]. Despite these controversial if not contradictory claims, preclinical experimental evidence of selegiline's neuroprotective properties [134,138] and data showing that rasagiline holds anti-oxidant and anti-apoptotic properties, which potentially translates into long-term neuroprotective benefits [26,125,134,138,139], argues in support of current use of these drugs as either monotherapy or taken as adjunctive with l-dopa for treating PD patients [139,140].…”

Protection Against Parkinson’s Disease Progression: Clinical Experience

“…Follow-up at 5 years revealed that selegiline significantly delayed the need for starting dopaminergic treatment. 39 In contrast to the other selegiline studies mentioned, this trial used an 8-week washout of selegiline, to eliminate possible symptomatic effects of MAO-B inhibition. Clinical outcomes for selegiline monotherapy or combined therapy with levodopa appeared to be improved, compared with treatment with placebo, although such studies present the challenge of sorting out symptomatic effects from neuroprotection.…”